Search hospitals > West Virginia > Huntington
Edwards Comprehensive Cancer Center
Claim this profileHuntington, West Virginia 25701
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
165 reported clinical trials
3 medical researchers
Summary
Edwards Comprehensive Cancer Center is a medical facility located in Huntington, West Virginia. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Edwards Comprehensive Cancer Center is involved with conducting 165 clinical trials across 320 conditions. There are 3 research doctors associated with this hospital, such as Mark Ranalli, Maria R. Tria Tirona, and Patricia H. Hardenbergh.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
PR positive
Top PIs
Mark RanalliNationwide Children's Hospital7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
69 reported clinical trials
120 drugs studied
Maria R. Tria TironaEdwards Comprehensive Cancer Center4 years of reported clinical research
Expert in Lung Cancer
Expert in Cancer
34 reported clinical trials
94 drugs studied
Patricia H. HardenberghShaw Cancer Center6 years of reported clinical research
Studies Breast Cancer
Studies Cancer
10 reported clinical trials
40 drugs studied
Clinical Trials running at Edwards Comprehensive Cancer Center
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Urothelial Carcinoma
Bladder Cancer
Recurrence
Endometrial Cancer
Solid Tumors
Ovarian Cancer
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Edwards Comprehensive Cancer Center?
Edwards Comprehensive Cancer Center is a medical facility located in Huntington, West Virginia. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Edwards Comprehensive Cancer Center is involved with conducting 165 clinical trials across 320 conditions. There are 3 research doctors associated with this hospital, such as Mark Ranalli, Maria R. Tria Tirona, and Patricia H. Hardenbergh.